Buprenorphine Treatment for Opioid Use Disorder: An Overview
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Opioid use disorder affects over 26 million individuals worldwide. There are currently three World Health Organization-recommended and US Food and Drug Administration-approved medication treatments for opioid use disorder: the full opioid agonist methadone, the opioid partial agonist buprenorphine, and the opioid receptor antagonist naltrexone. We provide a review of the use of buprenorphine for the treatment of opioid use disorder and discuss the barriers, challenges, risks, and efficacy of buprenorphine treatment vs. other treatments. Although evidence from numerous studies has shown buprenorphine to be effective for the treatment of opioid use disorder, a majority of patients with opioid use disorder do not receive buprenorphine, or any other medical treatment. We review the different formulations of buprenorphine, including newer long-acting injectable formulations that may decrease the risk of diversion and improve adherence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Release from prison–a high risk of death for former inmates
Binswanger, I. A., Stern, M. F., Deyo, R. A., Heagerty, P. J., Cheadle, A., Elmore, J. G., & Koepsell, T. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa064115 · Cited by 1,684
Degenhardt, L., Charlson, F., Ferrari, A., Santomauro, D., Erskine, H., Mantilla-Herrara, A., Whiteford, H., Leung, J., Naghavi, M., Griswold, M., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30337-7 · Cited by 1,572
Dole, V. P. (1965) · JAMA · doi:10.1001/jama.1965.03090080008002 · Cited by 1,240
Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005359 · Cited by 986
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60358-9 · Cited by 555
Self-citationWeiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
Hser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., et al. (2014) · Addiction · doi:10.1111/add.12333 · Cited by 455
Extended-release naltrexone to prevent opioid relapse in criminal justice offenders
Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., Wilson, D., McDonald, R., Rotrosen, J., Gourevitch, M. N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505409 · Cited by 315
Self-citation
Cited by
Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder
Schiff, D. M., Nielsen, T. C., Hoeppner, B. B., Terplan, M., Hadland, S. E., Bernson, D., Greenfield, S. F., Bernstein, J., Bharel, M., Reddy, J., et al. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.04.210 · Cited by 69
A comprehensive review of partial opioid agonists for the treatment of chronic pain
Gress, K., Charipova, K., Jung, J. W., Kaye, A. D., Paladini, A., Varrassi, G., Viswanath, O., & Urits, I. (2020) · Best Practice & Research Clinical Anaesthesiology · doi:10.1016/j.bpa.2020.06.003 · Cited by 36
Metadata
- Authors
- Shulman, M., Wai, J. M., & Nunes, E. V.
- Venue
- CNS Drugs
- Published
- 2019-05-06
- Volume
- 33
- Issue
- 6
- Pages
- 567-580
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2944736729
- Cited by
- 213
- References
- 16
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Buprenorphine Treatment for Opioid Use Disorder: An Overview. https://app.cochat.ai/papers/10.1007/s40263-019-00637-z
- The paper
- Shulman, M., Wai, J. M., & Nunes, E. V. (2019). Buprenorphine Treatment for Opioid Use Disorder: An Overview. CNS Drugs. https://doi.org/10.1007/s40263-019-00637-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.